Mono-Pt

Mono-Pt is a platinum-based chemotherapeutic agent, identified in the literature as a **monofunctional platinum complex**. Unlike classical platinum drugs such as cisplatin, Mono-Pt possesses only one leaving group, which restricts it to monofunctional DNA binding rather than cross-linking[1]. Its mechanism of action involves binding to DNA and inducing cytotoxic responses, but with potentially reduced off-target toxicity compared to bifunctional platinum drugs. Mono-Pt has been studied primarily in preclinical and early clinical contexts as an experimental cancer therapy, with reported activity against a range of tumor models in vitro and in vivo. The drug was first developed as part of efforts to create platinum-based anticancer molecules with improved selectivity and side effect profiles. Mono-Pt's exact developer is not clearly indicated in the publicly available literature, but it is associated with academic research into platinum drug design.

Brand names

Mono-Pt

Other names

Mono-Pt